Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 7/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475766 | 1.00 | FPR2 (0.58) | FPR2FOLH1CNR1LMNAATM | |
| SCHEMBL13677845 | 1.00 | FPR2 (0.58) | FPR2FOLH1CNR1LMNAATM | |
| SCHEMBL13677850 | 0.91 | FOLH1 (0.55) | FPR2FOLH1CNR1LMNACCKBR | |
| SCHEMBL6375965 | 0.89 | LMNA (0.67) | FPR2FOLH1CNR1LMNAATM | |
| SCHEMBL6373220 | 0.84 | FPR2 (0.74) | FPR2FOLH1CNR1LMNAATM | |
| SCHEMBL6379735 | 0.84 | FPR2 (0.74) | FPR2LMNAALDH1A1MAPK1MAPT | |
| SCHEMBL6374130 | 0.84 | FPR2 (0.74) | FPR2LMNAALDH1A1MAPK1MAPT | |
| SCHEMBL6374120 | 0.84 | FPR2 (0.74) | FPR2LMNAALDH1A1MAPK1MAPT | |
| SCHEMBL6374157 | 0.84 | FPR2 (0.74) | FPR2FOLH1CNR1LMNAATM | |
| SCHEMBL6381454 | 0.84 | FPR2 (0.74) | FPR2FOLH1CNR1LMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585730-B1 | CARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-7598241-B2 | 2-[3-(4-chlorophenyl)ureido] N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-4-methanesulfonylbutyramide; prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20060074072-A1 | Carboxamide derivatives and their use as factor xa inhibitors | MERCK PATENT GMBH (DE) | 2006-04-06 | — | — | US | disclosed |
| EP-1585730-A1 | CARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004065369-A1 | CARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074072-A1 | Carboxamide derivatives and their use as factor xa inhibitors | F11, F12, F10 | FPR2 454/4885FOLH1 1288/4885CNR1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.